Skip to main content

Sertraline treatment of panic disorder: results of a long-term study

Buy Article:

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.

Objective: To investigate the long-term efficacy, prevention of relapse and safety of sertraline in the treatment of panic disorder.

Method: This study consisted of 52 weeks of open-label sertraline treatment (n=398) followed by a 28 weeks of a double-blind, placebo-controlled discontinuation trial (n=183).

Results: Ninety-three patients were randomized to sertraline and 90 were randomized to placebo. Discontinuation due to insufficient clinical response occurred in 23.6% of placebo-treated patients and 12.0% of sertraline-treated patients (log-rank test, P=0.040). Thirty-three per cent of placebo-treated patients had an exacerbation of panic symptomatology, versus 13% of sertraline-treated patients (log-rank test, P=0.005). Abrupt cessation of sertraline resulted in dizziness (4.3% sertraline vs. 16.9% placebo; P=0.007) and insomnia (4.3% sertraline vs. 15.7% placebo; P=0.013) occurring at significantly higher rates.

Conclusion: Long-term sertraline treatment was effective in preventing relapse of panic disorder, well tolerated and associated with minimal discontinuation symptoms.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: SSRI; agoraphobia; antidepressant agents; panic disorder; serotonin uptake inhibitors; sertraline; side effects; treatment outcome

Document Type: Research Article

Publication date: 2001-10-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more